Log In
Print
BCIQ
Print
Print this Print this
 

Benlysta, belimumab (formerly LymphoStat-B)

Also known as: IV Benlysta

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionIV formulation of BLyS (BAFF)-specific inhibitor
Molecular Target BLyS (BAFF)
Mechanism of ActionBinds BLyS; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$3,000.0M

$3,000.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today